655 related articles for article (PubMed ID: 22207601)
1. Effects of surface modification of PLGA-PEG-PLGA nanoparticles on loperamide delivery efficiency across the blood-brain barrier.
Chen YC; Hsieh WY; Lee WF; Zeng DT
J Biomater Appl; 2013 Mar; 27(7):909-22. PubMed ID: 22207601
[TBL] [Abstract][Full Text] [Related]
2. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters.
Gelperina S; Maksimenko O; Khalansky A; Vanchugova L; Shipulo E; Abbasova K; Berdiev R; Wohlfart S; Chepurnova N; Kreuter J
Eur J Pharm Biopharm; 2010 Feb; 74(2):157-63. PubMed ID: 19755158
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
4. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123.
Tosi G; Costantino L; Rivasi F; Ruozi B; Leo E; Vergoni AV; Tacchi R; Bertolini A; Vandelli MA; Forni F
J Control Release; 2007 Sep; 122(1):1-9. PubMed ID: 17651855
[TBL] [Abstract][Full Text] [Related]
5. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
6. Surface modified PLGA nanoparticles for brain targeting of Bacoside-A.
Jose S; Sowmya S; Cinu TA; Aleykutty NA; Thomas S; Souto EB
Eur J Pharm Sci; 2014 Oct; 63():29-35. PubMed ID: 25010261
[TBL] [Abstract][Full Text] [Related]
7. Effects of surface modification on delivery efficiency of biodegradable nanoparticles across the blood-brain barrier.
Kulkarni SA; Feng SS
Nanomedicine (Lond); 2011 Feb; 6(2):377-94. PubMed ID: 21385139
[TBL] [Abstract][Full Text] [Related]
8. Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles.
Ren T; Xu N; Cao C; Yuan W; Yu X; Chen J; Ren J
J Biomater Sci Polym Ed; 2009; 20(10):1369-80. PubMed ID: 19622277
[TBL] [Abstract][Full Text] [Related]
9. Ultrafine PEG-coated poly(lactic-co-glycolic acid) nanoparticles formulated by hydrophobic surfactant-assisted one-pot synthesis for biomedical applications.
Chu CH; Wang YC; Huang HY; Wu LC; Yang CS
Nanotechnology; 2011 May; 22(18):185601. PubMed ID: 21415469
[TBL] [Abstract][Full Text] [Related]
10. Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution.
Tosi G; Vergoni AV; Ruozi B; Bondioli L; Badiali L; Rivasi F; Costantino L; Forni F; Vandelli MA
J Control Release; 2010 Jul; 145(1):49-57. PubMed ID: 20338201
[TBL] [Abstract][Full Text] [Related]
11. Brain-derived neurotrophic factor delivered to the brain using poly (lactide-co-glycolide) nanoparticles improves neurological and cognitive outcome in mice with traumatic brain injury.
Khalin I; Alyautdin R; Wong TW; Gnanou J; Kocherga G; Kreuter J
Drug Deliv; 2016 Nov; 23(9):3520-3528. PubMed ID: 27278330
[TBL] [Abstract][Full Text] [Related]
12. Transferrin-conjugated nanoparticles of poly(lactide)-D-alpha-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier.
Gan CW; Feng SS
Biomaterials; 2010 Oct; 31(30):7748-57. PubMed ID: 20673685
[TBL] [Abstract][Full Text] [Related]
13. Polysorbate 80-coated PLGA nanoparticles improve the permeability of acetylpuerarin and enhance its brain-protective effects in rats.
Sun D; Xue A; Zhang B; Lou H; Shi H; Zhang X
J Pharm Pharmacol; 2015 Dec; 67(12):1650-62. PubMed ID: 26407669
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
15. Brain targeting with surface-modified poly(D,L-lactic-co-glycolic acid) nanoparticles delivered via carotid artery administration.
Tahara K; Miyazaki Y; Kawashima Y; Kreuter J; Yamamoto H
Eur J Pharm Biopharm; 2011 Jan; 77(1):84-8. PubMed ID: 21074612
[TBL] [Abstract][Full Text] [Related]
16. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
17. Etoposide encapsulation in surface-modified poly(lactide-co-glycolide) nanoparticles strongly enhances glioma antitumor efficiency.
Callewaert M; Dukic S; Van Gulick L; Vittier M; Gafa V; Andry MC; Molinari M; Roullin VG
J Biomed Mater Res A; 2013 May; 101(5):1319-27. PubMed ID: 23065812
[TBL] [Abstract][Full Text] [Related]
18. Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration.
Semete B; Booysen L; Kalombo L; Ramalapa B; Hayeshi R; Swai HS
Int J Pharm; 2012 Mar; 424(1-2):115-20. PubMed ID: 22227605
[TBL] [Abstract][Full Text] [Related]
19. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides.
Li J; Feng L; Fan L; Zha Y; Guo L; Zhang Q; Chen J; Pang Z; Wang Y; Jiang X; Yang VC; Wen L
Biomaterials; 2011 Jul; 32(21):4943-50. PubMed ID: 21470674
[TBL] [Abstract][Full Text] [Related]
20. Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers.
Geldenhuys W; Wehrung D; Groshev A; Hirani A; Sutariya V
Pharm Dev Technol; 2015 Jun; 20(4):497-506. PubMed ID: 24597667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
